Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2096985 | 0.99 | MAPT (0.51) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| Hydrochloric Acid SCHEMBL2096987 | 0.99 | MAPT (0.51) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL9923321 | 0.86 | MAPT (0.63) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL1116773 | 0.84 | MAPT (0.59) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL9918357 | 0.83 | MAPT (0.52) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL1022293 | 0.80 | POLB (0.47) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL31726480 | 0.79 | ALDH1A1 (0.56) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL6949058 | 0.77 | MAPT (0.74) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL16969338 | 0.76 | MAPT (0.48) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL4761820 | 0.75 | MAPT (0.42) | MAPTALDH1A1LMNAALOX12NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118305-A1 | COMPOUNDS | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | disclosed |
| EP-1517907-B1 | AZABICYCLO-OCTANE AND NONANE DERIVATIVES WITH DDP-IV INHIBITING ACTIVITY | SANOFI AVENTIS (FR) | 2011-01-12 | — | — | EP | disclosed |
| US-7781455-B2 | Compounds | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20050153973-A1 | (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; enzyme inhibitors; diabetes | SANOFI-AVENTIS (FR) | 2005-07-14 | — | — | US | disclosed |
| EP-1517907-A2 | AZABICYCLO-OCTANE AND NONANE DERIVATIVES WITH DDP-IV INHIBITING ACTIVITY | Sanofi-Aventis (FR) | 2005-03-30 | — | — | EP | disclosed |
| WO-2003106456-A2 | NEW COMPOUNDS | SANOFI-SYNTHELABO (FR) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153973-A1 | (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; enzyme inhibitors; diabetes | DPP4, DPP8, DPP3 | MAPT 3740/4885ALDH1A1 558/4885LMNA 3746/4885 |
| US-20110118305-A1 | COMPOUNDS | DPP4, DPP3, DPP8 | MAPT 2950/4885ALDH1A1 599/4885LMNA 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.